you are viewing a single comment's thread.
Higgins holding out for the big bucks! Still 700000 shares short. Can't see anyone maintaining their short position into ASKO. Make them pay up for your shares $14-15.
I let it go the first time, but... well... it's ASCO. Not ASKO.It you want a biotech with a material ASCO catalyst, you'll need to look elsewhere. $LGND does have a nice catalyst with the SARMs ENDO poster. Still, as a Ph1B, we expect the good news is priced in, but a report of any serious adverse effects (not expected) is not.